Redhill Biopharma Ltd America (RDHL) Covered Calls

You can sell covered calls on Redhill Biopharma Ltd America to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for RDHL (prices last updated Wed 4:16 PM ET):

Redhill Biopharma Ltd America (RDHL) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
8.15 -0.16 5.25 8.91 98K - 0.2B
Covered Calls For Redhill Biopharma Ltd America (RDHL)
Expiration Strike Call Bid Net Debit Return
If Flat
Return If Flat
Mar 15 7.5 0.40 8.51 -11.9% -181.0%
Apr 18 7.5 0.70 8.21 -8.6% -54.1%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, and in-licensed/acquired drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company commercializes three gastrointestinal products in the United States, such as Donnatal, a prescription oral adjunctive drug used in the treatment of irritable bowel syndrome (IBS), and acute enterocolitis and duodenal ulcers; EnteraGam, a prescription medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools; and Esomeprazole Strontium Delayed-Release Capsules 49.3 mg, a prescription proton pump inhibitor drug product indicated for adults for the treatment of GERD, risk reduction of NSAID-associated gastric ulcer, Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence, and for pathological hypersecretory conditions. Its clinical-stage development programs include TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection with an ongoing confirmatory Phase III study and successful results from a first Phase III study; RHB-104 with an ongoing first Phase III study for Crohn's disease and a planned pivotal Phase III study for nontuberculous mycobacteria infections; BEKINDA (RHB-102) with positive results from a Phase III study in acute gastroenteritis and gastritis, and positive results from a Phase II study in IBS-D; YELIVA (ABC294640), a SK2 selective inhibitor, targeting multiple oncology, inflammatory, and gastrointestinal indications with an ongoing Phase IIa study for cholangiocarcinoma; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; and RHB-107 (MESUPRON), a Phase II-stage serine protease inhibitor targeting gastrointestinal and other solid tumor cancers. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.